Skip to main content
Fig. 3 | EJNMMI Research

Fig. 3

From: Prospective comparison of [18F]AlF-NOTA-octreotide PET/MRI to [68Ga]Ga-DOTATATE PET/CT in neuroendocrine tumor patients

Fig. 3

a Maximum-intensity projections and sagittal images of [18F]AlF-OC, [68Ga]Ga-DOTATATE PET and of [68Ga]Ga-DOTATATE PET 4 months after aforementioned scans of a 55-year-old female patient with a pancreatic NET with multiple bone metastases. b Transverse PET images with two concordant bone lesions on [18F]AlF-OC and [68Ga]Ga-DOTATATE (blue arrows) and two incremental bone lesions with [18F]AlF-OC (green arrows). Both incremental bone lesions were visible on the next clinical follow-up [68Ga]Ga-DOTATATE scan 4 months later (orange arrow), as well as a new bone lesion (red arrow). c Transverse PET images showing one concordant bone lesion on both scans (blue arrow) and one incremental bone lesion with [18F]AlF-OC (green arrow). The incremental bone lesion had no corresponding lesion on MRI, but the next clinical follow-up [68Ga]Ga-DOTATATE scan 4 months later (orange arrow) showed obvious tracer uptake

Back to article page